Israel Gives Final Go-Ahead for Cannabis Exports: Here's Who Could Profit -- CFN Media

June 01, 2020 8:00 AM EDT | Source: CFN Enterprises Inc.

Santa Monica, California--(Newsfile Corp. - June 1, 2020) - CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the leading media network dedicated to the global legal cannabis, CBD and psychedelics industries, today announces an article discussing Israel's recent approval for cannabis exports and how companies like Isracann Biosciences, Inc. (CSE: IPOT) (OTC Pink: ISCNF) are well-positioned to profit.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/6612/56902_0b367488d4fd381b_001full.jpg
Isracann Biosciences, Inc.

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6612/56902_0b367488d4fd381b_001full.jpg

Israel gave final approval in mid-May for exports of medical cannabis, paving the way for more than one billion shekels ($273 million) in annual revenue. The country will become one of just three countries that have approved the export of medical cannabis to countries that permit its use-after Canada and the Netherlands- when the law goes into effect on June 13, 2020.

With its favorable climate and expertise in medical and agricultural technologies, Israel could become one of the world's biggest producers of medical cannabis. iCAN estimates the global market for Israel's medical cannabis could be as high as $33 billion, while Israeli companies like Syqe Medical have pioneered innovative medical cannabis technologies.

The go-ahead to export medical cannabis could open the door to new investment in the country, while existing Israeli producers, like Isracann Biosciences Inc. (CSE: IPOT) (OTC Pink: ISCNF), could be well-positioned to benefit from near-term export demand.

Let's take a look at who stands to profit from the recent export decision and how investors can position themselves to capitalize on the developments.

Who Stands to Profit?

There are more than ten farms and five factories in Israel that meet the Health Ministry's standards for medical cannabis exports, and several of them have already reached agreements to sell cannabis to Europe or Canada when licenses become available.

Isracann Biosciences Inc. (CSE: IPOT) (OTC Pink: ISCNF) is Israel's first pure-play cannabis firm wholly focused on becoming the nation's premier, low-cost cannabis producer. The company has a joint venture agreement in place with a built 55,000 sq. ft. farm that's expandable to 110,000 sq. ft. in the near-term and has access to over two million sq. ft. of private land.

"Our Hefer Valley farm is making great strides," said Isracann's VP of Operations, Matt Chatterton in a recent press release. "We engaged a specialist Israeli consultant to advance the certification of farm to EU-GMP standards thereby paving the way for our export distribution. In addition, the related post-harvest export facility is nearing readiness."

In addition to its production, Isracann entered into a MOU earlier this year to distribute cannabis throughout European end markets. The distributor will import products through the Republic of Malta, subject to compliance and regulations, and is currently preparing a regional processing facility designed to meet EU-GMP standards.

Breath of Life International Ltd. planned to raise C$150 million on the Toronto Stock Exchange (TSE) through a public share offering priced at C$27 to C$32 per share last year, but management shelved plans for an IPO until market conditions improved in October 2019. The company reported $1.1 million in revenue during the first quarter of 2019 from the Israeli market.

Click here to view an exclusive interview with Isracann's CEO Darryl Jones:



Cannot view this video? Visit:
https://www.youtube.com/watch?v=XXhtd4lYAlk

Other Israeli cannabis producers that could benefit include:

  • Cronos Group Inc. has a strategic joint venture with Kibbutz Gan Shmuel, a commercial farming community, whereby it plans to build a 45,000 sq. ft. greenhouse in Israel that will help supply the European market.

  • Aura Health Inc. holds convertible debt that converts to a 54% equity position in HolyCanna, a cultivation and nursery license in Israel. The company also signed a LOI with CannabiSendak to build a high-profile dispensary in Tel Aviv.

  • Namaste Technologies Inc. owns a 10% stake in Cannbit, a licensed cannabis operation in Israel. The company also has a collaboration and supply agreement with the company to purchase medical cannabis.

What's Next for Israel?

Israel's move to legalize medical cannabis exports could be transformative for many public and private companies operating in the country. Investors looking for exposure to the space may want to consider Isracann Biosciences Inc. (CSE: IPOT) (OTC Pink: ISCNF) as one of the only pure-plays in the space or a handful of other companies that have exposure through joint ventures and investments.

Learn more about Isracann Biosciences by downloading their investor presentation or visiting their website.

Click here to read the full article:
https://www.cannabisfn.com/israel-gives-final-go-ahead-for-cannabis-exports-heres-who-could-profit

About CFN Enterprises Inc.

CFN Enterprises Inc. (OTCQB: CNFN) is a digital media and ecommerce company focused on advancing businesses and brands in highly regulated emerging industries across the globe. CFN connects investors with new market opportunities while helping consumers find innovative products that enhance their lives. Learn more at www.cfnenterprisesinc.com.

CFN Enterprises Inc. Media Contact:

CFN Enterprises Inc.
+001 (833) 420-CNFN
investors@cfnenterprisesinc.com

Frank Lane - President
Flane@cannabisfn.com

FORWARD-LOOKING STATEMENT

Use of Forward-looking Statements

This press release may contain forward-looking statements from CFN Enterprises Inc. within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. For example, when CFN Enterprises Inc. describes the potential acquisition of BarNone assets and the related benefits, its pursuit of M&A opportunities, growth in CBD sales and spending on affiliate marketing, and uses other statements containing the words "believes," "anticipates," "plans," "expects," "will" and similar expressions, CFN Enterprises Inc. is using forward-looking statements. These forward-looking statements are based on the current expectations of the management of CFN Enterprises Inc. only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: regulatory and licensing risks; changes in general economic, business and political conditions, including changes in the financial markets; the regulatory landscape and enforcement related to cannabis, including political risks and risks relating to regulatory change; changes in applicable laws; compliance with extensive government regulation; public opinion and perception of the cannabis industry; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products and services; or, loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of CFN Enterprises Inc. to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, CFN Enterprises Inc. undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risk and uncertainties affecting CFN Enterprises Inc., reference is made to CFN Enterprises Inc.'s reports filed from time to time with the Securities and Exchange Commission.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/56902

info